



# BLISS GVS PHARMA LIMITED

CIN: L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

## AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2015

### PART-I (₹ in Lacs)

SR. No.	P A R T I C U L A R S	STANDALONE					CONSOLIDATED	
		QUARTER ENDED			YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED
		31.03.2015 (AUDITED)*	31.12.2014 (UNAUDITED)	31.03.2014 (AUDITED)	31.03.2015 (AUDITED)	31.03.2014 (AUDITED)	31.03.2015 (AUDITED)	31.03.2014 (AUDITED)
1	<b>Income From Operations</b>							
	(a) Net Sales ( Net of Excise Duty)	6,796.32	8,413.00	5,373.14	30,945.89	28,349.25	40,307.34	33,973.26
	(b) Other Operating Income	68.51	116.50	120.17	356.28	473.82	406.10	490.95
	<b>Total Income from Operations( Net)</b>	<b>6,864.83</b>	<b>8,529.50</b>	<b>5,493.31</b>	<b>31,302.17</b>	<b>28,823.07</b>	<b>40,713.44</b>	<b>34,464.21</b>
2	<b>Expenses</b>							
	a) Consumption of Raw Materials	2,946.33	4,041.61	2,969.99	13,784.13	13,517.82	16,456.36	15,554.08
	b) Purchase of Traded Goods	-	-	529.50	90.32	1,030.40	933.42	1,551.65
	c) (Increase)/Decrease in Stock in Trade	113.10	(150.56)	(369.38)	248.27	60.57	364.87	(42.67)
	d) Employee Benefit Expenses	469.38	458.74	340.48	1,736.08	1,292.61	2,942.90	2,346.28
	e) Depreciation / Amortisation	145.07	131.35	71.57	507.83	446.16	1,129.62	1,068.18
	f) Other Expenditure	2,040.08	1,786.92	1,363.94	6,823.95	6,314.46	9,671.97	7,932.83
	<b>Total Expenses</b>	<b>5,713.96</b>	<b>6,268.06</b>	<b>4,906.09</b>	<b>23,190.58</b>	<b>22,662.02</b>	<b>31,499.14</b>	<b>28,410.35</b>
3	<b>Profit from Operations Before other Income &amp; Finance Cost &amp; Exceptional Items ( 1-2)</b>	<b>1,150.87</b>	<b>2,261.44</b>	<b>587.21</b>	<b>8,111.59</b>	<b>6,161.05</b>	<b>9,214.30</b>	<b>6,053.86</b>
4	Other Income	213.17	850.05	145.68	2,135.03	3,012.42	2,028.86	2,800.19
5	<b>Profit from ordinary activities before Finance Cost (3+4)</b>	<b>1,364.04</b>	<b>3,111.49</b>	<b>732.89</b>	<b>10,246.63</b>	<b>9,173.47</b>	<b>11,243.16</b>	<b>8,854.05</b>
6	Finance Cost	296.42	349.61	309.44	1,121.18	943.63	1,641.24	1,798.23
7	<b>Profit from ordinary activities after Finance Cost but before Exceptional Items (5-6)</b>	<b>1,067.61</b>	<b>2,761.88</b>	<b>423.45</b>	<b>9,125.45</b>	<b>8,229.84</b>	<b>9,601.92</b>	<b>7,055.82</b>
8	Exceptional Items	-	-	-	-	-	-	-
9	<b>Profit from Ordinary Activities Before Tax ( 7 - 8)</b>	<b>1,067.61</b>	<b>2,761.88</b>	<b>423.45</b>	<b>9,125.45</b>	<b>8,229.84</b>	<b>9,601.92</b>	<b>7,055.82</b>
10	Tax Expense (Including Deferred Tax)	421.51	962.62	272.00	3,123.90	2,837.19	3,462.58	2,952.67
11	<b>Net Profit for the Period (9 - 10)</b>	<b>646.10</b>	<b>1,799.26</b>	<b>151.45</b>	<b>6,001.55</b>	<b>5,392.65</b>	<b>6,139.34</b>	<b>4,103.15</b>
12	Minority Interest			-			(148.37)	(3.98)
13	<b>Net Profit after Tax &amp; Minority Interest (11-12)</b>	<b>646.10</b>	<b>1,799.26</b>	<b>151.45</b>	<b>6,001.55</b>	<b>5,392.65</b>	<b>5,990.97</b>	<b>4,099.17</b>
14	Paid - Up Equity Capital	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47
15	Reserves Excluding Revaluation Reserve (As Per Balance Sheet )			-	35,787.14	30,452.64	32,676.83	27,656.65
16	<b>Basic and Diluted EPS ( Not Annualised)</b>	<b>0.63</b>	<b>1.74</b>	<b>0.15</b>	<b>5.82</b>	<b>5.23</b>	<b>5.81</b>	<b>3.97</b>

### PART-II

SR. No.	P A R T I C U L A R S	STANDALONE					CONSOLIDATED	
		QUARTER ENDED			YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED
		31.03.2015 (AUDITED)*	31.12.2014 (UNAUDITED)	31.03.2014 (AUDITED)	31.03.2015 (AUDITED)	31.03.2014 (AUDITED)	31.03.2015 (AUDITED)	31.03.2014 (AUDITED)
A	<b>Particulars of Shareholding</b>							
1	Aggregate of Non-promoter Shareholding							
	- No. of Shares (face Value Rs.1/- Each)	36156842	36156842	36156842	36156842	36156842	36156842	36156842
	- Percentage of Shareholding (%)	35.05	35.05	35.05	35.05	35.05	35.05	35.05
2	Promoter and Promoter group Shareholding							
	A) Pledge / Encumbered							
	- No. of Shares (Face Value Re.1/- Each)	-	-	-	-	-	-	-
	- Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)	-	-	-	-	-	-	-
	- Percentage of Shares (as % of the Total Share Capital of The Company)	-	-	-	-	-	-	-
	B) Non - Encumbered							
	- No. of Shares (Face Value Re.1/- Each)	66989830	66989830	66989830	66989830	66989830	66989830	66989830
	- Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the Total Share Capital of The Company)	64.95	64.95	64.95	64.95	64.95	64.95	64.95

SR. No.	P A R T I C U L A R S	Quarter Ended 31st March 2015
B	<b>Investor Complaints</b>	
	Pending at the beginning of the quarter	-
	Received during the quarter	10
	Disposed off during the quarter	2
	Remaining unsolved at the end of the quarter	8

### STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2015. (₹ in Lacs)

SR. No.	P A R T I C U L A R S	STANDALONE		CONSOLIDATED	
		Mar-15	Mar-14	Mar-15	Mar-14
I.	<b>Equity and Liabilities</b>				
1	Shareholders' Funds :				
	(i) Share Capital	1,031.47	1,031.47	1,031.47	1,031.47
	(ii) Reserves and Surplus	35,787.14	30,452.64	32,676.83	27,656.65
	(iii) Money received against Share Warrants	-	-	-	-
	<b>Sub-total - Shareholders' Funds</b>	<b>36,818.61</b>	<b>31,484.11</b>	<b>33,708.30</b>	<b>28,688.12</b>
2	<b>Minority Interest</b>	-	-	<b>1,489.18</b>	<b>1,016.26</b>
3	<b>Non-Current Liabilities</b>				
	(i) Long Term Borrowings	3,020.95	4,513.54	5,725.81	8,758.83
	(ii) Deferred Tax Liabilities(Net)	715.30	619.80	885.94	695.79
	(iii) Long Term Provisions	139.85	110.33	139.85	110.33
	<b>Sub-total - Non-Current Liabilities</b>	<b>3,876.10</b>	<b>5,243.67</b>	<b>6,751.60</b>	<b>9,564.95</b>
4	<b>Current Liabilities</b>				
	(i) Short Term Borrowings	2,837.62	2,314.16	6,104.21	5,704.90
	(ii) Trade Payables	5,046.72	5,898.97	8,033.39	8,235.44
	(iii) Other Current Liabilities	3,913.46	2,851.53	7,030.05	4,211.63
	(iv) Short Term Provisions	3,007.62	847.01	3,100.09	857.26
	<b>Sub-total- Current Liabilities</b>	<b>14,805.42</b>	<b>11,911.67</b>	<b>24,267.74</b>	<b>19,009.23</b>
	<b>Total .....</b>	<b>55,500.13</b>	<b>48,639.45</b>	<b>66,216.82</b>	<b>58,278.56</b>
II.	<b>Assets</b>				
1	<b>Non-current Assets</b>				
	(a) Fixed Assets	8,150.39	5,783.71	16,062.00	14,394.36
	(b) Goodwill on Consolidation	-	-	7,376.00	7,369.64
	(c) Non-current Investments	1,922.63	1,922.53	1.01	1.01
	(d) Long Term Loans and Advances	10,135.08	10,917.86	1,026.79	1,201.57
	(e) Other Non Current Assets	43.26	142.37	43.26	142.36
	<b>Sub-total - Non-current Assets</b>	<b>20,251.36</b>	<b>18,766.47</b>	<b>24,509.06</b>	<b>23,108.94</b>
2	<b>Current Assets</b>				
	(a) Inventories	2,251.83	2,122.89	3,370.00	3,253.04
	(b) Trade receivables	21,061.21	18,353.25	24,746.94	21,502.59
	(c) Cash and Bank Balances	4,736.77	7,412.07	5,728.93	8,037.21
	(d) Short Term Loans and Advances	6,133.62	1,252.04	7,470.88	2,067.83
	(e) Other Current Assets	1,065.34	732.73	391.01	308.95
	<b>Sub-total- Current Assets</b>	<b>35,248.77</b>	<b>29,872.98</b>	<b>41,707.76</b>	<b>35,169.62</b>
	<b>Total .....</b>	<b>55,500.13</b>	<b>48,639.45</b>	<b>66,216.82</b>	<b>58,278.56</b>

#### Notes:

- The Company operates primarily in the Pharmaceutical Business and hence has only one reportable segment.
- The Consolidated Results includes the Audited Financial Results of parent company, the subsidiaries namely Bliss GVS International Pte Ltd (100% Holding), Bliss Indasi Life Sciences Pvt Ltd (51% Holding), Bliss GVS Clinic Healthcare Pte Ltd (100% Holding), Kremoint Pharma Pvt Ltd (70% Holding), Lifeon Labs Pvt Ltd (51% Holding), Asterisk Lifesciences Ltd (100% Holding) & step down subsidiaries.
- Tax expenses for the Quarter and Year Ended March 31<sup>st</sup>, 2015 includes short provision for earlier years Rs. 41.90 Lacs and Quarter and Year Ended March 31<sup>st</sup>, 2014 includes short provision of earlier years of Rs. 170.00 Lacs.
- The Board has Recommended a dividend of 50% i.e Re. 0.50 per Equity Share for the year Ended 31<sup>st</sup>, March 2015.
- \*The figures for the Quarter Ended March 31<sup>st</sup>, 2015 & 2014 are the balancing figures between the Audited Figures in respect of the full Financial Year and the year to date published results for the nine months ended December 31<sup>st</sup>, 2014 & 2013.
- The Company has recomputed the depreciation based on the useful life of the Assets as per Companies Act 2013. This has resulted in additional charge of depreciation of Rs. 126.45 Lacs for the Year Ended March 31<sup>st</sup>, 2015. Further, as per transitional provision of the Companies Act 2013, the Company has adjusted the written down value of Rs. 7.06 Lacs (Net of Deferred Tax of Rs. 2.40 Lacs) in the Opening Balance of surplus in Profit and Loss.
- Previous Year/Period Figures are regrouped/rearranged wherever necessary.
- The above results were reviewed by the Audit committee & were there after approved by the Board at its Meeting held on May 29<sup>th</sup> 2015.

FOR BLISS GVS PHARMA LIMITED  
SD/-

Place : Mumbai  
Date : 29th May 2015

S. N. KAMATH  
MANAGING DIRECTOR